Menopause
The permanent cessation of menstruation caused by the ovaries ceasing function — a turning point involving significant metabolic, cardiovascular, and bone changes that calls for deliberate prevention.
Number of studies
1
Safety
Moderate
Time to effects
Metabolic and bone changes build up gradually over the first several years from the last period.
Who it's for
Table of contents
TL;DR
The permanent cessation of menstruation caused by the ovaries ceasing function — a turning point involving significant metabolic, cardiovascular, and bone changes that calls for deliberate prevention.
- →Understanding the mechanism allows for deliberate planning of osteoporosis and cardiovascular disease prevention
- →Early bone density assessment enables intervention before osteoporotic fractures occur
- →Awareness of lipid profile changes helps intensify cardiovascular prevention at the right time
| Intervention type | A natural life stage, not an intervention |
|---|---|
| Level of evidence | Strong — the mechanism and health consequences are well documented in large studies |
| Target group | Women in the perimenopausal and postmenopausal periods |
| Time to effects | Metabolic changes build up over several years from the last period |
| Preparation needed | Bone density assessment (densitometry), lipid panel, cardiovascular risk assessment |
| Status | A natural life stage requiring deliberate prevention, not a disease in itself |
Understand
Overview
Menopause is the point of permanent cessation of menstruation due to the ovaries ceasing hormonal function, diagnosed retrospectively after 12 months without a period, usually between ages 45 and 55. Unlike the gradual decline in testosterone seen in men, the drop in estrogen during the perimenopausal period is much sharper and concentrated within a relatively short window of a few years.
The decline in estrogen affects the body far more broadly than just the menstrual cycle — it accelerates bone loss (increasing osteoporosis risk), unfavorably shifts the lipid profile, and raises cardiovascular risk to a level approaching that of men of the same age. The question of hormone replacement therapy (HRT) during this period was the subject of one of the most influential and controversial studies in the history of medicine — the Women's Health Initiative — which significantly changed global clinical practice.
Who can genuinely benefit from this? Every woman approaching the perimenopausal period — understanding the mechanism and predictable metabolic changes allows for deliberate prevention planning (bone density, cardiovascular health) instead of reacting only after the fact. The decision about possible hormone replacement therapy should always be made individually with a doctor, taking into account age, time since the last period, and individual risk factors.
Mechanism of action
Menopause occurs when the ovarian follicle reserve is depleted to the point where the ovaries stop responding to hormonal signals from the pituitary gland (FSH, LH) and no longer produce enough estrogen to sustain the menstrual cycle. In response to the lack of feedback, the pituitary increases FSH secretion — hence elevated FSH is one of the biochemical markers of the perimenopausal period.
Estrogen serves functions in the body that extend far beyond the reproductive system — it supports bone mineral density by inhibiting osteoclast activity (the cells that break down bone tissue), and favorably affects the lipid profile and vascular endothelial function. The sharp drop in estrogen at menopause removes these protective mechanisms almost simultaneously, which explains the accelerated bone loss and increased cardiovascular risk observed during this period.
Depletion of the ovarian follicle reserve
The ovaries gradually stop responding to hormonal signals from the pituitary gland.
Rise in FSH as a compensatory signal
The pituitary increases FSH secretion in response to the lack of feedback from the ovaries.
Loss of estrogen's protective effect on bone
The drop in estrogen weakens the inhibition of osteoclasts, accelerating bone loss.
Change in cardiovascular profile
The drop in estrogen unfavorably affects the lipid profile and vascular endothelial function.
Evidence: strong — based on 1 study in this database.
Benefits
Common myths
MythHormone replacement therapy is dangerous for every woman and should be avoided entirely.
FactThe benefit-risk balance of HRT depends strongly on the age at which therapy starts and the time since menopause — the decision should be individualized, not based on a generalization from a single study.
MythMenopause is only the end of menstruation, with no broader health consequences.
FactThe decline in estrogen significantly affects bone density, lipid profile, and cardiovascular risk, extending far beyond the reproductive system alone.
Forms & variants
Menopause comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Perimenopause
The transitional period with irregular cycles, preceding the last period.
Best for: Early implementation of prevention and monitoring
Menopause proper
Diagnosed retrospectively after 12 months without a period.
Best for: Cardiovascular and bone risk assessment
Premature menopause
Occurring before age 40, requiring in-depth diagnostic workup for the cause.
Best for: Requires endocrinology consultation
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
Most often between ages 45 and 55, with the average in most Western populations around age 51.
Yes — the decline in estrogen accelerates bone loss, which is why bone density assessment is an important part of prevention during this period.
Not automatically — the decision depends on individual risk profile, age, and time since menopause, so it always requires medical consultation.
Dosage & timing
Typical dose
Not applicable — a natural life stage, not an intervention with dosing
Form
Supporting diagnostics: FSH, estradiol, bone densitometry, full lipid panel
The decision about possible hormone replacement therapy is always made individually with a doctor, taking into account age, time since the last period, and risk profile.
Best times to take it
- Not applicable
Safety
Side effects & contraindications
Possible side effects
Not directly applicable — this entry describes a natural life stage, not an intervention
Contraindications
Not applicable
Interactions
Not directly applicable — any hormone replacement therapy has a separate interaction profile requiring individual medical assessment
Is it worth taking?
Who it's for
- Women in the perimenopausal and postmenopausal periods
- Women planning deliberate bone and cardiovascular health prevention
Not for
- Not applicable
Evidence
Worth knowing
Menopause is diagnosed retrospectively — only after 12 months of complete absence of periods.
The Women's Health Initiative study, published in 2002, significantly changed global clinical practice regarding hormone replacement therapy.
Studies
Estrogen-progestin hormone replacement therapy in healthy postmenopausal women was associated with both benefits and significant risks, underscoring the need to individualize the treatment decision rather than apply it routinely.
Rossouw JE et al. (Women's Health Initiative), JAMA, 2002
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Strong evidenceRossouw JE, Anderson GL, Prentice RL, et al. · JAMA · 2002
A large randomized trial assessing the benefit-risk balance of hormone replacement therapy in healthy postmenopausal women, which significantly changed clinical practice worldwide.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
268 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
196 publications on this site
Related entries
4.7Magnesium
A cofactor for more than 300 enzymatic reactions — essential for neuromuscular function, sleep and energy metabolism.
4.5Cortisol
The main stress hormone — essential for short-term survival, but problematic when chronically elevated.
4.9Mediterranean Diet
The best-studied eating pattern for cardiovascular health and longevity.
4.7Endometriosis
A chronic disease affecting about 10% of women of reproductive age, still diagnosed with a multi-year delay on average — despite pain severe enough to significantly disrupt daily functioning.
4.6Polycystic Ovary Syndrome (PCOS)
The most common hormonal disorder among women of reproductive age — it combines irregular cycles, excess androgens, and insulin resistance, but responds substantially to lifestyle changes.
4.7Testosterone
The primary anabolic hormone — its natural level depends heavily on sleep, resistance training, body composition and fat mass.
4.7Hashimoto's Thyroiditis
A chronic autoimmune thyroiditis and the most common — though often overlooked in discussions of hypothyroidism itself — cause of thyroid hormone deficiency in iodine-sufficient countries, affecting women several times more often than men.
4.6Hypothyroidism
One of the most common hormonal disorders, especially in women — it slows metabolism and is often mistaken for chronic fatigue or 'ordinary' weight gain.
Related articles
PoradnikiHormone Replacement Therapy in Menopause: Who Should Consider It, When, and What's the Real Risk?
The 2002 WHI study triggered a global panic around hormone replacement therapy, and prescriptions dropped by half almost overnight. Two decades of further analysis have painted a much more nuanced picture — one that depends above all on age and timing of initiation. We explain what the data actually show, who has a favorable risk-benefit balance today, and who should exercise particular caution.
August 22, 2026
Badania naukoweLongevity Vitamins: Which Supplements Actually Have Real Scientific Evidence Behind Them
Every supplement shelf promises a longer life in every capsule, but the hard data from large clinical trials tells a far more measured story. We go through which vitamins genuinely extend healthy lifespan in people with a real deficiency, and which — despite their popularity — have no supporting evidence at all, or worse, evidence of no benefit.
August 20, 2026
PoradnikiBlack Cohosh and Menopause Symptoms — What Does the Network Meta-Analysis Show?
Black cohosh (Actaea racemosa, also known as Cimicifuga racemosa) is one of the most popular herbal supplements for hot flashes and night sweats during menopause — marketed as a hormone-free alternative to hormone replacement therapy. A large network meta-analysis prepared for the UK's NICE menopause guideline did place it among the options more effective than placebo, but the picture is more nuanced than pharmacy packaging suggests.
August 27, 2026
PoradnikiDHEA After 40: Does Supplementing the "Youth Hormone" Make Sense?
DHEA (dehydroepiandrosterone) is a hormone produced by the adrenal glands whose level steadily declines from around age 25 — by age 70 it can be as much as 80% lower than in youth. This decline has made DHEA one of the most commonly supplemented "youth hormones" in the United States, where it's sold over the counter. But the largest, two-year randomized trial, published in the New England Journal of Medicine, found no evidence that supplementation restores muscle strength, improves body composition, or improves insulin sensitivity in aging men and women. We check where the evidence actually ends and the marketing begins.
September 4, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.